

Ref: FOI/GS/ID 6595

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

04 March 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Hereditary Angioedema (HAE).

You asked:

Q1. In the past 6 months [latest 6 months available] how many patients have received the following treatments [for any disease]:

- a. Berinert (Human C1-esterase inhibitor)*
- b. Cinryze (Human C1-esterase inhibitor)*
- c. Takhzyro (Lanadelumab)*
- d. Ruconest (Recombinant human C1-esterase inhibitor)*
- e. Firazyr (Icatibant injection)*

Q2. In the past 6 months [latest 6 months available] how many patients have received the following immunoglobulin treatments [for any disease]:

- a. Cuvitru*
- b. Gammanorm*
- c. Gamunex*
- d. Hizentra*
- e. Hyqvia*
- f. Kiovig*
- g. Octagam*
- h. Privigen*
- i. Subgam*

Q3. In the past 6 months, how many patients attended A&E for Hereditary Angioedema (ICD10 code: D84.1) or Angioedema (ICD10 code: T78.3)? Of these patients, how many were treated with the following products:

- a. Berinert (Human C1-esterase inhibitor)*
- b. Cinryze (Human C1-esterase inhibitor)*
- c. Ruconest (Recombinant human C1-esterase inhibitor)*
- d. Firazyr (Icatibant injection)*

Trust response:

Q1.

- a. 0
- b. 0
- c. 0
- d. 0
- e. 0

Q2.

- a. 0
- b. 1
- c. 15
- d. 4
- e. 0
- f. 0
- g. 0
- h. 134
- i. 0

Q3.

- a. 0
- b. 0
- c. 0
- d. 0